ECSP066392A - - Google Patents

Info

Publication number
ECSP066392A
ECSP066392A EC2006006392A ECSP066392A ECSP066392A EC SP066392 A ECSP066392 A EC SP066392A EC 2006006392 A EC2006006392 A EC 2006006392A EC SP066392 A ECSP066392 A EC SP066392A EC SP066392 A ECSP066392 A EC SP066392A
Authority
EC
Ecuador
Prior art keywords
receptors
activity
modulate
symptoms
disease
Prior art date
Application number
EC2006006392A
Other languages
English (en)
Spanish (es)
Inventor
Richard Martin
Tie-Lin Wang
Brenton T Flatt
Xiao-Hui Gu
Original Assignee
Ceptor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceptor Therapeutics Inc filed Critical Ceptor Therapeutics Inc
Publication of ECSP066392A publication Critical patent/ECSP066392A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2006006392A 2003-07-23 2006-02-23 ECSP066392A (https=)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48985403P 2003-07-23 2003-07-23

Publications (1)

Publication Number Publication Date
ECSP066392A true ECSP066392A (https=) 2007-01-26

Family

ID=34102943

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006392A ECSP066392A (https=) 2003-07-23 2006-02-23

Country Status (14)

Country Link
US (1) US8466143B2 (https=)
EP (1) EP1648408A4 (https=)
JP (1) JP4679517B2 (https=)
KR (1) KR20060052867A (https=)
CN (1) CN1852748A (https=)
AU (1) AU2004259009A1 (https=)
BR (1) BRPI0412262A (https=)
CA (1) CA2532798C (https=)
CR (1) CR8258A (https=)
EC (1) ECSP066392A (https=)
IL (1) IL173287A0 (https=)
NO (1) NO20060871L (https=)
RU (1) RU2006105646A (https=)
WO (1) WO2005009387A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
US20080161289A1 (en) 2005-03-14 2008-07-03 Glaxo Group Limited Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス, インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体
US20080299118A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for the Treatment of Malignancies
US20080300235A1 (en) * 2007-06-01 2008-12-04 Wyeth FXR Agonists for Reducing LOX-1 Expression
US20090163474A1 (en) * 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
US20090215748A1 (en) * 2007-12-20 2009-08-27 Wyeth FXR agonists for treating vitamin D associated diseases
AU2009308706C1 (en) 2008-10-31 2016-01-21 Medivation Technologies, Inc. Pyrido (4,3-b) indoles containing rigid moieties
WO2010051503A1 (en) 2008-10-31 2010-05-06 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
CN101875627B (zh) * 2009-04-30 2014-01-15 凯惠科技发展(上海)有限公司 一种1-烷氧羰基-2h-异吲哚衍生物及其制备方法和中间体
SG176100A1 (en) 2009-05-22 2011-12-29 Abbott Lab Modulators of 5-ht receptors and methods of use thereof
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
KR101770979B1 (ko) 2010-05-21 2017-08-24 애브비 인코포레이티드 5­ht 수용체의 조절제 및 이의 사용방법
US9434747B2 (en) 2011-02-18 2016-09-06 Medivation Technologies, Inc. Methods of treating diabetes
CN103476417A (zh) 2011-02-18 2013-12-25 梅迪维新技术公司 治疗糖尿病的化合物和方法
EP2887805A4 (en) * 2012-08-22 2016-08-17 Medivation Technologies Inc COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
CA2968434A1 (en) 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
CN107438612A (zh) * 2014-12-22 2017-12-05 阿卡纳治疗学有限公司 用于治疗疾病的稠合双环化合物
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
AU2016238523A1 (en) 2015-03-26 2017-11-09 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
WO2017143134A1 (en) * 2016-02-19 2017-08-24 Alios Biopharma, Inc. Fxr modulators and methods of their use
BR112018073460A2 (pt) * 2016-05-25 2019-07-09 Akarna Therapeutics Ltd terapias combinadas usando moduladores do receptor farnesoide x (fxr)
MX2018014034A (es) * 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
CN111542319A (zh) * 2017-06-02 2020-08-14 阿卡纳治疗学有限公司 稠合的双环化合物
MA51679A (fr) * 2018-01-26 2020-12-02 Exelixis Inc Composés destinés au traitement de troubles dépendant de la kinase
UA128348C2 (uk) 2018-01-26 2024-06-19 Екселіксіс, Інк. Сполуки для лікування кіназозалежних розладів

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR35044B (el) 1966-05-10 1968-07-31 The Upjohn Company Μεθοδος παρασκευης οργανικων ενωσεων.
US4362739A (en) * 1981-05-04 1982-12-07 S.A. Omnichem Pyrrolo(2,3-d)carbazole derivatives, compositions and use
IL101851A (en) * 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv 10-(4-piperidinyl- and piperidinylidene)-imidazo [1,2-a] (pyrrolo thieno or furano) [2,3] azepine derivatives their preparation and pharmaceutical compositions containing them and certain novel intermediates therefor
JPH09221475A (ja) * 1996-02-13 1997-08-26 Yamanouchi Pharmaceut Co Ltd 新規なオキシム誘導体
AU8766498A (en) * 1997-08-04 1999-02-22 Amgen, Inc. Hydroxamic acid substituted fused heterocyclic metalloproteinase inhibitors
SG121853A1 (en) 1999-06-18 2006-05-26 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising hdl using atp binding cassette transporter protein abc1
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
MY122278A (en) * 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US20020013334A1 (en) * 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
JP5420908B2 (ja) * 2005-12-15 2014-02-19 エグゼリクシス, インコーポレイテッド 医薬的薬剤としてのアゼピノインドール誘導体

Also Published As

Publication number Publication date
JP2006528637A (ja) 2006-12-21
EP1648408A1 (en) 2006-04-26
CA2532798C (en) 2013-02-19
CR8258A (es) 2006-08-30
KR20060052867A (ko) 2006-05-19
CN1852748A (zh) 2006-10-25
US8466143B2 (en) 2013-06-18
WO2005009387A2 (en) 2005-02-03
RU2006105646A (ru) 2007-09-10
AU2004259009A1 (en) 2005-02-03
US20070015746A1 (en) 2007-01-18
JP4679517B2 (ja) 2011-04-27
WO2005009387A3 (en) 2006-03-02
BRPI0412262A (pt) 2006-09-19
CA2532798A1 (en) 2005-02-03
NO20060871L (no) 2006-04-24
EP1648408A4 (en) 2006-11-29
IL173287A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
ECSP066392A (https=)
CR8497A (es) Derivados de azepinoindol como agentes farmaceuticos
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
MX2007005205A (es) Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
NO20081788L (no) Cyklopropylaminer som modulatorer av histamin-H3-reseptoren
TW200607491A (en) Aryl sulfonamide and sulfonyl compounds as modulators of ppar and methods of treating metabolic disorders
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
NI200900031A (es) Compuestos de n-metilaminometil isoindol y composiciones que los comprenden y métodos para usar los mismos.
UY26130A1 (es) Compuestos para tratar la obesidad
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
BRPI0513677B8 (pt) derivados de pirrol como agentes farmacêuticos
PA8570701A1 (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparacion
NO20054407L (no) Cannabinoid reseptor ligander og deres anvendelser
NO20081160L (no) Benzimidazoltiofen forbindelser
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
GT200300054A (es) Compuestos que modulan la actividad de ppar
GT200300053A (es) Compuestos que modulan la actividad de ppar
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
ECSP077270A (es) Ácidos de tiazolo - naftilo
UY27851A1 (es) Difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
BRPI0511527A (pt) compostos e composições como moduladores de ppar
ATE472529T1 (de) Prolinamidderivate als natriumkanalmodulatoren
ECSP077130A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de náuseas y vómitos